Lilly(Eli) & Co (NYSE: LLY) Is Getting Increasingly Hard To Ignore

Currently, there are 948.10M common shares owned by the public and among those 849.76M shares have been available to trade.

The company’s stock has a 5-day price change of -12.44% and -6.17% over the past three months. LLY shares are trading 0.40% year to date (YTD), with the 12-month market performance up to 2.54% higher. It has a 12-month low price of $677.09 and touched a high of $972.53 over the same period. LLY has an average intraday trading volume of 3.88 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.80%, -6.51%, and -7.99% respectively.

Institutional ownership of Lilly(Eli) & Co (NYSE: LLY) shares accounts for 73.14% of the company’s 948.10M shares outstanding.

It has a market capitalization of $734.61B and a beta (3y monthly) value of 0.48. The stock’s trailing 12-month PE ratio is 64.21, while the earnings-per-share (ttm) stands at $12.07. The company has a PEG of 1.54 and a Quick Ratio of 1.06 with the debt-to-equity ratio at 2.44. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.22% over the week and 4.49% over the month.

Earnings per share for the fiscal year are expected to increase by 69.18%, and 35.29% over the next financial year. EPS should grow at an annualized rate of 41.76% over the next five years, compared to 18.77% over the past 5-year period.

Looking at the support for the LLY, a number of firms have released research notes about the stock. HSBC Securities stated their Reduce rating for the stock in a research note on April 28, 2025, with the firm’s price target at $1150-$700. Cantor Fitzgerald coverage for the Lilly(Eli) & Co (LLY) stock in a research note released on April 22, 2025 offered a Overweight rating with a price target of $975. BofA Securities was of a view on December 10, 2024 that the stock is Buy, while Wolfe Research gave the stock Outperform rating on November 15, 2024, issuing a price target of $1000. Bernstein on their part issued Outperform rating on October 17, 2024.

Most Popular

Related Posts